Lantheus (LNTH) Holdings announced that it has received U.S. Food and Drug Administration, FDA, tentative approval for the Abbreviated New Drug Application, ANDA, for Lutetium Lu 177 Dotatate, a radioequivalent version of Lutathera. Lutathera is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LNTH: